Biomarkers of immune response in mucosal lesions and their use with therapeutic vaccination
AssigneeThe Johns Hopkins University
InventorCornelia Trimble
Life of this patent
Estimating the term…
Abstract
The present invention provides evidence of post-vaccination immunologic changes in target HPV induced cervical intraepithelial neoplasias that suggest the induction of clinically relevant tissue-localized immune responses, despite modest detectable responses in circulating T lymphocytes. The inventive methods allow for identification of immunological responses to HPV immunotherapies, and means for monitoring responses during clinical trials and treatment regimens.
Claims17
A method for determining the effectiveness of an HPV vaccine regimen on a subject having a cervical intraepithelial neoplasia (CIN) comprising:
- a) obtaining at least one first tissue sample from the CIN of the subject;
- b) administering to the subject a first vaccine construct comprising HPV16 E7 antigen one or more times;
- c) administering to the subject a second vaccine construct comprising both E6 and E7 antigens from both HPV16 and HPV18;
- d) obtaining at least one or more second tissue samples from the CIN of the subject about 4 to about 24 weeks after step c);
- e) measuring the amount of CD8+ T cell infiltrates in the intraepithelial tissue of the first and second CIN samples;
- and f) determining that the HPV vaccine regimen is effective when the amount of CD8+ T cell infiltrates in the second tissue sample is increased when compared to the amount of CD8+ T cell infiltrates in the first tissue sample.
A method for treating a subject having a cervical intraepithelial neoplasia (CIN) comprising:
- a) obtaining at least one first tissue sample from the CIN of the subject;
- b) administering to the subject a first vaccine construct comprising HPV16 E7 antigen one or more times;
- c) administering to the subject a second vaccine construct comprising both E6 and E7 antigens from both HPV16 and HPV18;
- d) obtaining at least one or more second tissue samples from the CIN of the subject about 4 to about 24 weeks after step c);
- e) measuring the amount of CD8+ T cell infiltrates in the intraepithelial tissue of the first and second CIN samples;
- and f) determining that the HPV treatment is effective when the amount of CD8+ T cell infiltrates in the second tissue sample is increased when compared to the amount of CD8+ T cell infiltrates in the first tissue sample.
A method for determining the effectiveness of an HPV vaccine regimen with an adjuvant on a subject having a cervical intraepithelial neoplasia (CIN) comprising:
- a) obtaining at least one first tissue sample from the CIN of the subject;
- b) administering to the subject an effective amount of a first vaccine construct comprising HPV16 E7 antigen one or more times;
- c) administering to the subject an effective amount of a second vaccine construct comprising both E6 and E7 antigens from both HPV16 and HPV18, and an effective amount of an adjuvant;
- d) obtaining at least one or more second tissue samples from the CIN of the subject about 4 to about 24 weeks after step c);
- e) measuring the amount of CD8+ T cell infiltrates in the intraepithelial tissue of the first and second CIN samples;
- and
- f) determining that the HPV treatment is effective when the amount of CD8+ T cell infiltrates in the second tissue sample is increased when compared to the amount of CD8+ T cell infiltrates in the first tissue sample.
A method for treating a subject having a cervical intraepithelial neoplasia (CIN) comprising:
- a) obtaining at least one first tissue sample from the CIN of the subject;
- b) administering to the subject an effective amount of a first vaccine construct comprising HPV16 E7 antigen one or more times;
- c) administering to the subject an effective amount of a second vaccine construct comprising both E6 and E7 antigens from both HPV16 and HPV18, and an effective amount of an adjuvant;
- d) obtaining at least one or more second tissue samples from the CIN of the subject about 4 to about 24 weeks after step c);
- e) measuring the amount of CD8+ T cell infiltrates in the intraepithelial tissue of the first and second CIN samples;
- and
- f) determining that the HPV treatment is effective when the amount of CD8+ T cell infiltrates in the second tissue sample is increased when compared to the amount of CD8+ T cell infiltrates in the first tissue sample.
Dependencies are inferred from the claim text.